Survey Report:
The Novel Coronavirus Pandemic and the State of the Epidemic in Kobe, Japan
Noriko Nakanishi and Yoshio Iijima
Department of Infectious Diseases, Kobe Institute of Health
4-6-5 Minatojima-nakamachi, Chuo-ku, Kobe, Hyogo 650-0046, Japan
Corresponding author
The outbreak of the novel coronavirus disease (COVID-19), caused by the SARS-CoV-2 virus, occurred in Wuhan, China in December 2019 and quickly spread to both the developed and developing countries. The virus will continue to infect humans and animals symptomatically or asymptomatically, and humans will be expected to coexist with SARS-CoV-2 by preventing infections and its spread. In this paper, we report on the occurrence of the COVID-19 epidemic in Japan, including the city of Kobe.
- [1] Wikipedia, “List of Natural Disasters by Death Toll,” https://en.wikipedia.org/wiki/List_of_natural_disasters_by_death_toll [accessed October 20, 2020]
- [2] Wikipedia, “World War II Casualties,” https://en.wikipedia.org/wiki/World_War_II_casualties [accessed October 20, 2020]
- [3] J. Tortorice, “The Deadliest Pandemics in History,” 2020, https://ceufast.com/blog/the-deadliest-pandemics-in-history [accessed October 30, 2020]
- [4] N. Zhu et al., “A Novel Coronavirus from Patients with Pneumonia in China, 2019,” N. Engl. J. Med., Vol.382, No.8, pp. 727-733, 2020.
- [5] C. Huang et al., “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China,” The Lancet, Vol.395, Issue 10223, pp. 497-506, 2020.
- [6] Q. Li et al., “Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia,” N. Engl. J. Med., Vol.382, No.13, pp. 1199-1207, 2020.
- [7] Y. Furuse and H. Oshitani, “Viruses That Can and Cannot Coexist With Humans and the Future of SARS-CoV-2,” Front. Microbiol., Vol.11, Article No.583252, doi: 10.3389/fmicb.2020.583252, 2020.
- [8] K. Shirato et al., “Development of Genetic Diagnostic Methods for Detection for Novel Coronavirus 2019 (nCoV-2019) in Japan,” Jpn. J. Infect. Dis., Vol.73, No.4, pp. 304-307, 2020.
- [9] Ministry of Health, Labour and Welfare, Japan, “Outbreak of pneumonia associated with a new type of coronavirus (case 1),” https://www.mhlw.go.jp/stf/newpage_08906.html (in Japanese) [accessed October 20, 2020]
- [10] Y. Furuse et al., “Epidemiology of COVID-19 Outbreak in Japan, from January–March 2020,” Jpn. J. Infect. Dis., Vol.73, No.5, pp. 391-393, 2020.
- [11] Y. Furuse et al., “Clusters of Coronavirus Disease in Communities, Japan, January–April 2020,” Emerg. Infect. Dis., Vol.26, No.9, pp. 2176-2179, doi: 10.3201/eid2609.202272, 2020.
- [12] H. Oshitani and the Experts Members of the National COVID-19 Cluster Taskforce at the Ministry of Health, Labour and Welfare, Japan, “Cluster-Based Approach to Coronavirus Disease 2019 (COVID-19) Response in Japan–February–April 2020,” Jpn. J. Infect. Dis., Article ID JJJD.2020.363, doi: 10.7883/yoken.JJID.2020.363, 2020.
- [13] M. Kuroda, “Investigation of molecular epidemiology of genome of novel coronavirus SARS-CoV-2 in Japan 2,” 2020, https://www.niid.go.jp/niid/images/research_info/genome-2020_SARS-CoV-MolecularEpidemiology_2.pdf (in Japanese) [accessed October 20, 2020]
- [14] T. Sekizuka et al., “SARS-CoV-2 Genome Analysis of Japanese Travelers in Nile River Cruise,” Front. Microbiol., Vol.11, Article No.1316, doi: 10.3389/fmicb.2020.01316, 2020.
- [15] T. Sekizuka et al., “Haplotype networks of SARS-CoV-2 infections in the Diamond Princess cruise ship outbreak,” Proc. of the National Academy of Sciences, Vol.117, No.33, pp. 20198-20201, 2020.
- [16] T. Sekizuka et al., “A genome epidemiological study of SARS-CoV-2 introduction into Japan,” medRxiv, doi: 10.1101/2020.07.01.20143958, 2020.
- [17] City of Kobe, “Comparison of infection status for each period,” https://www.city.kobe.lg.jp/a89138/hikaku.html (in Japanese) [accessed October 26, 2020]
- [18] City of Kobe, “Analysis site of Kobe City for novel coronavirus countermeasures,” https://www.city.kobe.lg.jp/a89138/coronataisaku.html (in Japanese) [accessed October 26, 2020]
This article is published under a Creative Commons Attribution-NoDerivatives 4.0 Internationa License.